Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke "MACSI"


Phase 3 Results N/A



  • Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008 Jun;39(6):1774-8. Epub 2008 Apr 10. Pubmed ID:18403736
  • Rosenberg G, Angel I, Kozak A. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. Br J Clin Pharmacol. 2005 Jul;60(1):7-16. Pubmed ID:15963088
  • Barkalifa R, Hershfinkel M, Friedman JE, Kozak A, Sekler I. The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death. Eur J Pharmacol. 2009 Sep 15;618(1-3):15-21. Epub 2009 Jul 19. Pubmed ID:19622352
  • Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K; for the MACSI investigators. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal Phase III study. Int J Stroke. 2011 Aug;6(4):362-367. Epub 2011 Jun 6. Pubmed ID:21645269
  • Rosenberg G, Marshall LS, Caraco Y. The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro. Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):289-92. Epub 2010 Dec 16. No abstract available. Pubmed ID:21414144

Sources for Trial Information